Drugs / Carfentanil
Carfentanil
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05528848 | Sep 2022 → Sep 2027 expected | substance-related disorder | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 1 | NCT00618631 | Jan 2008 → Jan 2015 | substance-related disorder | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carfentanil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00618631 ↗ |
| Known as | [11C]Carfentanil | “[11C]Carfentanil” NCT05528848 ↗ |
| Known as | Carfentanil, C-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528848 ↗ |
| Modality | Diagnostic / imaging agent | “mu-opioid PET receptor radioligand” NCT00618631 ↗ |
| Route | Intravenous | “Each participant will receive ≤ 10 mCi of [11C]carfentanil intravenously” NCT05528848 ↗ |